Cerebral Array II from Randox Biosciences
Cerebral Array II from Randox Biosciences
13 August 2020
Cerebral Array II from Randox Biosciences
Randox Biosciences’ Cerebral Array II has been designed for the simultaneous measurement of analytes associated with nervous system dysfunctions such as Alzheimer’s disease and multiple sclerosis. The array harnesses multiplex testing measuring up to five biomarkers simultaneously using a single patient sample with a turnaround time of 2.5 hours. It is suitable for human serum, plasma and cerebrospinal fluid (CSF) samples. Our Cerebral Array II offers excellent sensitivity, precision and recovery as well as analytical performance.
Cerebral Array II
- C-Reactive Protein (CRP)
- D-Dimer
- Neuron Specific Enolase (NSE)
- Neutrophil Gelatinase-Associated Lipocalin (NGAL)
- Soluble Tumour Necrosis Factor Receptor I (sTNFRI)
Key Benefits of Cerebral Array II
- Multiplex testing from a single sample
- Suitable for human serum, plasma and cerebrospinal fluid (CSF) samples
- Small sample volume
- Excellent analytical performance
- Fast throughput
- Applicable to fully automated and semi-automated Evidence platforms
Your central nervous system is your body’s control centre which includes the spinal cord and a large network of nerves and neurons. Together, the nervous system controls everything from your senses to the muscles throughout your body. When this is damaged, triggered by an illness or injury it can disturb many functions including memory, sensation and even a person’s personality.1 Up to 1 billion people (1 in 6 of the world’s population) suffer from neurological disorders from Alzheimer and Parkinson Disease, strokes, multiple sclerosis and epilepsy.2
World Health Organisation (WHO) categorizes neurological disorders in two groups which is shown in the table below3. Group one is classified as neurological disorders in neuropsychiatry which are non-communicable diseases (NCD). NCD is a disease that is not transmissible directly from one person to another. Group two are disorders/injuries with neurological sequelae meaning a pathological condition resulting from a prior disease, injury, or attack.
| GROUP ONE | GROUP TWO |
| Epilepsy | Cerebrovascular disease |
| Alzheimer and Other Dementias | Neuroinfectious |
| Parkinson’s Disease | Nutritional deficiencies and neuropathies |
| Multiple Sclerosis | Neurological injuries |
| Migraine |
Randox Biosciences can assist in cerebrovascular research by providing innovative diagnostic technology and tests that will continue to revolutionise the healthcare industry and assist in academic research. This technology includes our Evidence Investigator and our Cerebral Array II which can be used to assist in the discovery and research of Cerebral diseases.
Biochip Technology
Biochip Technology is an immunoassay testing platform and is the core of Randox Biosciences. The intelligent chemically activated 9x9mm ceramic biochip acts as a solid phase reaction vessel. Benefits of Biochip Technology include:
- The biochips are pre-fabricated with discrete test regions (DTR’s)
- Highly accurate testing
- Better diagnosis
- Reduced sample volume
- Wide test menu
- Multiple sample types can be used on a Biochip
- Cost consolidation
Evidence Investigator
The Evidence Investigator offers a high throughput even as a compact, semi-automated analyser promoting lab efficiency and cost saving solutions. Utilising Randox’s patented Biochip Technology, this platform facilitates multiplex testing in a rapid, accurate and easy-to-use format providing a comprehensive patient profile from one single sample. This analyser is suitable for medium throughput laboratories and is extremely robust with only one moving part.
For further information on our Cerebral Array please visit the Randox Biosciences website.
For any other enquiries please email info@randoxbiosciences.com
References:
RESEARCH
BIOPHARMA
CLINICAL LAB
BIOREAGENTS
We Are Randox | Staff Newsletter January – July 2020 Edition
Staff Newsletter January - July 2020 Edition
We are delighted to be able to share with you the January – July 2020 edition of our We Are Randox staff newsletter.
Click here to view our news from 2020 so far – including of course our vital work in testing for COVID-19, but also a range of staff announcements including engagements, births and retirements.
** Please note that this newsletter works most efficiently in your Google Chrome browser**
Dr Peter FitzGerald: “Nothing will ever be the same again.”
Dr Peter FitzGerald: Nothing will ever be the same again.
An Interview with Ulster Business Editor John Mulgrew in The Belfast Telegraph, in which Dr FitzGerald speaks to John about developing and helping roll out millions of tests for Covid-19, a forever changed society, the high likelihood of a similar pandemic returning and when a vaccine for the virus could be found.
Dr Peter FitzGerald’s expertise and opinion has probably never been taken as seriously as it has in the last few months.
“Nothing will be the same again,” he tells Ulster Business. And, of course, he’s right.
His firm Randox – based in Antrim – has been on the front line of testing for Covid-19 right across the UK and beyond. And as a result, he’s hired hundreds of new staff and built a £30m testing lab to deal with additional deluge of work resulting from a global pandemic unlike anyone here has ever seen.
“I think there is a reasonable chance there will be more pandemics, with globalisation and increased population,” he told Ulster Business. “I have no idea how much it will come back again in second wave.
“We know we have the capacity as a company to respond, and respond well. I suspect the country is going to be better prepared… it’s hard to predict.”
The medical testing giant’s first involvement with the current coronavirus strain began back in January, before it became an increasingly concerning dinner conversation in homes across Northern Ireland.
“In late January, research called and were looking at doing a test,” Peter said. “We downloaded the genetic sequence of the virus and spent the next two weeks developing a test. We can do it very quickly, as we already had coronaviruses on chip.
“It was sent to Public Health England, which took a while to prove it. We then got a contract to test for the NHS… we were doing what we thought was for the national good.”
The initial deal didn’t include all of the UK, but Randox is now also testing Northern Ireland.
“We do the testing and we have different analysers that do the testing as well, which we sell to labs across the world.”
The virus has led to a new complete lab being built (in which Peter is pictured in) to deal with the additional testing. “We decided to accelerate the manufacturing in our Randox Science Park in Antrim,” he says.
As a result, it has hired around 200 staff in the space of six to eight weeks to deal with the surge.
“Because we had closely related strains of the virus, it was wasn’t so difficult to modify our tests to allow for slightly different variations… once we got the contract we soon realised that we didn’t have enough lab space to deal with the ramp up.
“We then decided to be 33,000 sq ft of new lab space, and it was needed in three weeks. We got that done – work was 24 hours a day, and seven days a week. It’s now operating well. That has been very important in the process.”
Randox had a workforce of around 1,450 worldwide before the coronavirus crisis began, but has since taken on around 280 additional staff for a range of roles, partly in ramping up demand for the additional testing.
“A lot were being taken on a temporary basis but many will be permanent. We are not sure of the final numbers, but well over 100.” Those roles include scientists, manufacturers, and engineers.
“Nothing will be the same again,” Peter says. “What it has done is heightened the importance of testing. People sometimes don’t know what we do here at Randox… but people now realise.
“In the end, it’s a good thing. We are advocates of testing. It identities disease before symptoms occur and can save lives in many occasions. It saves lives and saves costs. It fits in with what we have been trying to do for years… as far as we are concerned, it’s the silver lining.
“We have customers worldwide and other products kept going. We moved around 100 scientists into Covid-related things and then they have gone back to normal jobs as we bring in new people.
“Some of our R&D projects have changed, new systems and new analysers allow for efficient and accurate testing.”
Peter says that just a small element of the business has seen a decrease amid the crisis, while other areas around Covid-19 have grown. “Only a small element of core business decreased. But our Covid and other genetic products have increased… overall sales will be up and by end of year normal business up as well.”
As a result of the latest expansion and growth across the business, generally speaking, Peter says the workforce looks set to climb to 1,650, with around 500-600 based at its main headquarters, just outside Antrim.
Peter’s also keen to reiterate the importance of Northern Ireland and its people to Randox. “This is our home base. It’s where we do our primary R&D and manufacturing. We also have a facility in Donegal.”
And, could all of this happen again soon, with a further outbreak or a similarly devastating strain or pandemic?
“(We are) more prepared and our technology is getting more accepted through bio chips. Early detection is a very important next stage. You don’t want people who have a cough or fever to think they have Covid all the time. That is where testing comes in and that differentiates.”
Peter says the next stop forward in a bid to address similar future incidents it also understanding how our immune systems work – better.
“The other major step forward in many ways is understanding the immune system better. How to better respond to infection. This will be very important.
“Some people are susceptible, and this could be genetic. (It’s about) working on certain genes in those who may have a bad attack. It will prepare humans better, the body’s defence, dealing with it as well.
“I have a deficiency in a particular gene which means I’m more susceptible to respiratory (conditions) but the spin-off of the gene means I’m less susceptible to certain cancers. This is the issue – it is so complex. One could be a strength and one moment, a weakness.”
And as for the formulation of a proven vaccine, Peter says: “I would say it would be well into next year.”
For further information please email randoxpr@randox.com
Photo Credit Elaine Hill
Want to know more about Randox?
Contact us or visit our homepage to view more.
Our Randox Products and Services
REAGENTS
RX SERIES
ACUSERA
BIOCHIP
Drug and Alcohol Training from Randox Testing Services
10 August 2020: Drug and Alcohol Training from Randox Testing Services
As well as providing a fully managed drug & alcohol testing service, RTS provide a range of training and education services to help inform and educate regarding the issue of drug & alcohol use in the workplace.
Alcohol use increases the risk of problems in the workplace, such as absenteeism, presenteeism and inappropriate behaviour. Use of alcohol or illicit drugs can impair a person’s performance at work through poor decision making and impaired reaction times causing lost productivity, inferior goods/services, errors and accidents.
Certain working situations and conditions are associated with use of alcohol and illicit drugs (i.e. shift or night work, travel away from home, working remotely, business meals, poor communications and job stress, etc). There are many factors within the workplace culture that present an increased risk for the use of substances including availability, work/peer-group pressures, lack of supervision, physical danger and interface with a demanding or aggressive public. International evidence also indicates that longer working hours are significantly associated with higher rates of alcohol use and related problems.
Professional Services
Randox Testing Services offer professional training services to ensure efficient implementation of workplace drug and alcohol testing. The training services confirm employer confidence to carry out workplace drug and alcohol testing and management competence in enforcing the process. There are a range of tailored training programmes to educate employers and their management staff.
Range of Courses
Our range of competency courses are designed to train employees who will be responsible for carrying out self-collection in accordance with company policy. Anyone involved in self-collection needs to be suitably trained and certificated to follow set procedures that ensure all testing can be legally defended. We provide competency courses for the following matrices:
- Alcohol Testing
- Instant Urine Testing
- Instant Oral Fluid Testing
In addition to the above, we also provide a portfolio of other training and education presentations that enable employers to enhance awareness of substance misuse & understand the various processes involved when implementing a workplace testing programme. These options include:
- Chain of Custody Training
- Drug & Alcohol Awareness Training
- Employee Briefings
- Bespoke Training Courses
All training courses are fully recorded, regularly reviewed and include an assessment of the effectiveness of training. Upon completion, all attendees are granted a Certificate of Attendance at the end of each completed training course.
Randox Testing Services
Randox Testing Services are a specialist in the workplace drug & alcohol testing sector. We provide a wide range of testing for companies who want to reduce the impact of substance misuse in the workplace. With a range of service options and expert staff on hand to provide help and training, our services will help to eradicate the impact of drugs and alcohol.
If you have any questions regarding drug & alcohol testing and how we can provide your company with training and education services, please use the below details to get in touch and we will be happy to discuss requirements.
Email – testingservices@randox.com
Phone – +44 (0) 28 9445 1011
Want to know more?
Contact us or visit our website to read more.
Update on Sample Kits
STATEMENT FROM RANDOX: 07 August 2020
Randox Laboratories have today taken the decision to recall Covid-19 sample collection kits, following the identification of incomplete EC certification. On 15th July DHSC placed these kits on hold due to the absence of swab certification from an external supplier. To date, Randox have not been provided with evidence to satisfactorily support the CE marking for these swabs. So, noting the lack of CE certification by the supplier and that some kits remain in the field at this time Randox has, as a regulatory measure, initiated the recall of those kits used within the National Testing Programme.
Randox Laboratories will continue to provide high volume Covid-19 testing to the National Testing Programme from their laboratories, based on sample collection kits from other providers.
DHSC have stated the risk to safety is low and test results from Randox kits are not affected.
This recall applies only to sample collection kits within the UK National Test and Trace Programme. Randox private customers or kits are not affected.
Press enquiries should be emailed to randox@newcenturymedia.co.uk
Randox in the media
Latest News
FAQs
Protected: Analysis of results from the QCMD Coronavirus Preparedness EQA Pilot Study
Ergot Alkaloids ELISA now available from Randox Food Diagnostics
28 July 2020
Ergot Alkaloid ELISA now available from Randox Food Diagnostics
Available now, the Randox Food Diagnostics Ergot Alkaloid ELISA (Catalogue Number EA3491) is:
Compliant with the lowest proposed maximum levels being considered by the European Commission for the total of 12 main ergot alkaloids applicable from July 2020, including the stricter drafted limits from July 2022, for cereal-based feed, wheat and rye milling products.
Accurately detects the sum of 12 main ergot alkaloids to test the most affected type of cereal – rye flour. Randox’s ELISA results show an excellent 95% correlation with the assigned concentration within FAPAS Proficiency Test scheme.
Unrivalled in the detection of low contamination levels. The Z-score of FAPAS PT of -0.6 for baby multigrain food was obtained using Randox Ergot Alkaloids ELISA.
Validated based on Commission Regulation (EC) No 519/2014 as a semi-quantitative screening method for cereal-based feed, wheat and rye milling products. The same regulation was followed for fit-for-purpose approach assessment for confirmatory method, which approves Randox Ergot Alkaloids ELISA as being a method for official control. It is successfully assessed by fit-for-purpose approach according to Commission Regulation (EC) No 401/2006 as approved method of analysis.
Evaluated by third-party laboratory (Wageningen Food Safety research / WFSR, 2019) and proved to be able to distinguish between negative and positive samples. Randox’s ELISA displayed no false-negatives and no false-positives in this study. Across all commercially available ELISA tests, Randox Food Diagnostics Ergot Alkaloids ELISA was the only test which showed good performance with all 3 sample types, including 11 matrices and a total of 24 samples.
Reference reports are available upon request.
For more information visit https://www.randoxfood.com/feed-and-cereals-analysis/ergot-alkaloids/ or email us directly at info@randoxfooddiagnostics.com
Want to know more?
Contact us or visit our Randox Food Diagnostics website.
Related Products
Meat & Seafood
Milk
Honey
Wine
COVID-19 Testing Service Testimonial: The Irish Football Association
COVID-19 Testing Service Testimonial: The Irish Football Association
As we move towards a new ‘normal’ and sporting organisations begin the process of restarting their games, many teams will be wondering how to ensure a safe and reassuring training environment for their players and their staff.
Thanks to our COVID-19 testing service, The Irish Football Association was able to facilitate a timely and efficient return to play by confirming their players as ‘COVID-safe.’
Our ‘Back to Business’ programme has enabled the IFA to demonstrate their commitment to their players, their staff, and their fans, as well as get back to business by ensuring the highest level of safety.
Corinne Lannie, Risk Manager at the Irish Football Association, commented;
“The test kits were very straightforward to use. The instructions were clear as was the YouTube guidance video. The recording onto the Randox system was easy and the speed of results was exceptional.
“The support provided by Paul (Randox Business Development Executive) was amazing – he was extremely helpful and supportive and really went above and beyond.”
At Randox, we offer two types of testing;
PCR (diagnostic) testing, and antibody testing, which can give an indication that an individual has been previously infected with COVID-19.
Sample collection services are available.
David Hallendorff, Business Relations Manager at Randox Health commented;
“Collectively we are all working towards a timely return to a more normal society, which will see companies reopening and people returning to work.
“To facilitate this recovery of the economy, without compromising the health of workers or of the wider general public, workplaces have a responsibility to provide a safe working environment.
“It is great to see so many companies putting the health of their staff as a priority and taking a proactive approach to testing.”
To find out more about our Back to Business COVID-19 Testing Service, please email info@randoxhealth.com or phone 0800 2545 130
Want to find out more?
Click one of the links below.
COVID-19 Products and Services
HOME TEST
ANTIBODY TEST
TESTING SERVICE
LABORATORY TOOLS
Chicago’s Rising Fentanyl Problem: A Randox Toxicology Report
Chicago’s Rising Fentanyl Problem: A Randox Toxicology Report
Abuse of opioids, and in particular, fentanyl, has been on the rise in the United States in recent years. The number of patients being prescribed painkillers has almost quadrupled since the 90s from 76 million to 289 million in 2016. It has been described as a uniquely American problem, where pain relief prescriptions are about 40% higher than other developed countries.
Inevitably due to the high addiction rate of opioids, this has unfortunately led to increasing overdose deaths. In 2017 alone over 70,000 people died from drug overdoses in the USA with opioids being involved in 67.8% of cases.
Chicago Illinois is no exception to this crisis. The National Institute of Drug Abuse found that Illinois has a rate of 17.2 deaths per 100,000 people from opioid overdoses, compared to the national average of 14.6. It is not only prescription painkillers that are adding to the opioid addiction crisis in Chicago, but substances such as fentanyl that is illegally sold on the street.
Fentanyl is a cheaper, synthetic opioid which can be 50 times more potent than heroin and 100 times more potent than morphine. It is commonly added to heroin to increase strength and cut costs. Many users believe they are purchasing heroin when in fact it can be mostly fentanyl, resulting in rising overdose deaths. The DEA’s Chicago lab have stated that the drug is making up a more of their workload than ever and becoming a regular drug they see.
Randox Toxicology
Randox Toxicology are world leaders in drug testing solutions with the capability of detecting over 500 drug and drug metabolites using our innovative Biochip Array Technology – the most comprehensive on the drug testing market. Using our revolutionary patented Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyzer that enables on-site simultaneous detection of up to 21 classical, prescription and synthetic drugs of abuse from a single sample.
Designed to work across a variety of matrices including; whole blood, urine, and oral fluid our patented multi-analyte testing platform provides a complete and highly accurate toxicology profile in 17-20 minutes. Most impressively the MultiSTAT has been designed to be fully operated from sample input to results output by someone with absolutely no laboratory experience and in any environment.
To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com
Randox Toxicology Products and Services
BIOCHIP
EVIDENCE
ELISA
MATRICES
Want to know more about Randox?
Contact us or visit our homepage to view more.
Temporary Precautionary Measure
STATEMENT FROM RANDOX: TEMPORARY PRECAUTIONARY MEASURE
16 July 2020
As an immediate precautionary measure we have temporarily suspended distribution of sample collection kits using one particular batch / supplier of swabs. This is a temporary measure and does not apply to our private business which uses a different supplier of swabs.
Test results from Randox kits are not affected.
For more information please contact the Randox PR team by emailing randoxpr@randox.com